InvestmentMay 26, 2026, 05:12 PM
Nanobiotix Closes Global Offering, Raises $100M Gross Proceeds
AI Summary
Nanobiotix S.A. announced the closing of its global offering, which included the full exercise of the underwriters' option for additional American Depositary Shares (ADSs). The offering generated approximately $100 million in aggregate gross proceeds. The company plans to allocate 50-60% of the net proceeds to advance its Nanoprimer and other platforms, 30-40% for general corporate purposes, and less than 10% for JNJ-1900 development. This capital raise is expected to fund the company's operations into 2029.
Key Highlights
- Nanobiotix closed its global offering, raising approximately $100 million in aggregate gross proceeds.
- The offering included the full exercise of the underwriters' option for additional ADSs.
- A total of 2,218,467 Ordinary Shares and 345,099 pre-funded warrants were issued.
- The subscription price was 33.60 per Ordinary Share, corresponding to $38.98 per ADS.
- 50-60% of net proceeds will advance Nanoprimer and other platforms.
- 30-40% of net proceeds are allocated for general corporate purposes.
- Less than 10% of net proceeds will support JNJ-1900 (NBTXR3) development.
- The company expects the net proceeds to meet working capital requirements into 2029.
Price Impact
More from NBTX